Clinical Research, Pharma & Healthcare FinancingGilead to Acquire Ouro Medicines for T Cell Engager ProgramBusiness WireMarch 24, 2026March 25, 2026 by Business WireMarch 24, 2026March 25, 2026016 Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio Gilead Intends to Enter into a...
